{
  "id": 921024,
  "title": "Outlook Therapeutics director Ghiath Sukhtian buys $2.5m in shares",
  "url": "https://urgent.news/2026/08/15/outlook-therapeutics-director-ghiath-sukhtian-buys-2-5m-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-15T00:16:05.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/outlook-therapeutics-director-ghiath-sukhtian-buys-25m-in-shares-93CH-4861653"
  },
  "original_language": "en",
  "account": "Ghiath Sukhtian, a director and 10% owner of Outlook Therapeutics, boosted his ownership in the company by purchasing $2.5 million worth of shares and warrants on August 12, 2026. Sukhtian, through his entity GMS Ventures, bought 2,525,252 shares at $0.99 per share, while also acquiring 2,525,252 warrants to purchase additional shares at $1.1 per share, with no separate payment required. The warrants, exercisable immediately upon issuance, were set to expire on August 14, 2031. Sukhtian, who holds a controlling interest in GMS Ventures, is considered a director by deputization, with two representatives on the Issuer’s board. Despite recent market volatility leading to the stock trading at $0.76, which is below its purchase price, the acquisition is seen as undervalued by AI analysis. Outlook Therapeutics reported a narrowed fiscal third-quarter loss, launching its newly approved eye drug LYTENAVA in the U.S., which has been approved by the FDA.",
  "summary": null,
  "key_points": [
    "Outlook Therapeutics director Ghiath Sukhtian bought $2.5m in shares and warrants.",
    "Sukhtian purchased 2,525,252 shares at $0.99 each and 2,525,252 warrants at $1.1 each.",
    "The warrants expire on August 14, 2031, and are considered undervalued by AI analysis."
  ],
  "editors_take": "This purchase signals Sukhtian's confidence in Outlook Therapeutics' prospects, particularly after the recent launch of its FDA-approved eye drug LYTENAVA in the U.S. and despite current market volatility.",
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Outlook Therapeutics CFO Kenyon acquires 101,010 shares",
        "url": "https://urgent.news/2026/08/15/outlook-therapeutics-cfo-kenyon-acquires-101-010-shares",
        "published": "2026-08-15T00:05:14.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}